Compare DexCom, Inc. (DXCM) vs Nutrien Ltd (NTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Nutrien Ltd — how do they compare? DexCom, Inc. trades at $84.11 (market cap $31.86B), while Nutrien Ltd trades at $67.48 (market cap $33.31B). The key difference: DexCom, Inc. and Nutrien Ltd are close in size by market cap, and Nutrien Ltd pays a 3.15% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Nutrien Ltd for 59 Days on average.
| DXCM | NTR | |
|---|---|---|
Market Cap | $31.86B | $33.31B |
Volume | 3,607,070 | 1,330,729 |
Sector | Health | Basic Materials |
52-Week High | $92.34 | $83.94 |
52-Week Low | $54.84 | $53.64 |
Typical Hold Time | 62 Days | 59 Days |
Enterprise Value | $31.32B | $45.11B |
Dividend Yield | — | 3.15% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.41, showing modest daily gains of 0.13%. The stock demonstrates strong fundamental performance with consistent earnings beats and robust revenue growth from $2.9B in 2022 to $4.66B in 2025. Profit margins have expanded significantly to 17.93%, while analyst sentiment remains overwhelmingly positive with 81% buy ratings. Recent news highlights the company's focus on Type 2 diabetes market expansion and leadership appointments.
DXCM presents a compelling growth story with expanding profitability and market opportunities, though elevated valuation multiples and technical bearish signals warrant caution. The consensus price target of $95.07 suggests 13% upside potential, but investors should monitor competitive pressures and reimbursement challenges in the CGM market.
Nutrien (NTR) trades at $69.87, down 0.14% with bearish technical signals despite recent earnings beats. The company shows improving fundamentals with Q1 2026 EPS beating expectations at $0.51 versus $0.48, though Q2 2026 missed at $2.61. Revenue trends show recovery from $26.0B in 2024 to $26.9B in 2025, with net income margin improving to 8.44%. Recent news highlights mixed sentiment with stock volatility following geopolitical fertilizer developments.
The outlook remains cautiously optimistic with analyst consensus at $76.14 target (8.9% upside) and 60.6% buy ratings. Key opportunities include strong potash demand and cost discipline, while risks involve fertilizer price volatility and competitive pressures from potential Belarus deals. Cash flow trends show consistent operational strength despite negative net flows.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Nutrien Ltd
Created in 2018 as a result of the merger between PotashCorp and Agrium, Nutrien is the world's largest fertilizer producer by capacity. Nutrien produces the three main crop nutrients--nitrogen, potash, and phosphate--although its main focus is potash, where it is the global leader in installed capacity with roughly 20% share. The company is also the largest agricultural retailer in the United States, selling fertilizers, crop chemicals, seeds, and services directly to farm customers through its brick-and-mortar stores and online platforms.
Read more on NTR →
